Research Highlights

Since its inception, MNC has published over 1000+ peer-reviewed journal articles (25,200 total citations). Over half of these publications (550+) have occurred in the last 5 years. Highlights include:

Psychosis and Developmental Neuropsychiatry Group
Group leader: Prof Christos Pantelis, MB BS, MD (Melb), Hon MD (Athens), MRCPsych, FRANZCP

  1. Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature 511 (7510), 421-427.
  2. Fornito et al. (2012). Schizophrenia, neuroimaging and connectomics. Neuroimage 62 (4), 2296-2314.
  3. Bora et al. (2012). Gray matter abnormalities in major depressive disorder: a meta-analysis of voxel based morphometry studies. Journal of Affective Disorders 138 (1), 9-18.
  4. YĆ¼cel et al. (2012). The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin 38 (2), 316-330.
  5. Skafidis, Testa, Zantomio, Chana, Everall, Pantelis (2014). Predicting the diagnosis of autism spectrum disorder using gene pathway analysis. Molecular Psychiatry 19, 504-510.

Clinical Neuropsychiatry Group
Group leader: Prof. Dennis Velakoulis, MBBS, Dip Crim, FRANZCP, MMed, DMed Sci

  1. Dazan et al. (2012). Volumetric abnormalities predating the onset of schizophrenia and affective psychoses: An MRI study in subjects at ultrahigh risk of psychosis Schizophrenia Bulletin 38, 1083-1091.
  2. Linberg et al. (2012). Hippocampal shape analysis in Alzheimer's disease and frontotemporal lobar degeneration subtypes. Journal of Alzheimers Disease 30, 355-365.
  3. Berger et al. (2012). Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. a longitudinal MRI/MRS study. Current Pharmaceutical Design 18, 570-57.
  4. Bora et al. (2015). Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer's disease: A meta-analysis. Journal of Neurology Neurosurgery and Psychiatry 86, 714-719.
  5. Solowij et al. (2013). Alteration to hippocampal shape in cannabis users with and without schizophrenia. Schizophrenia Research. 143, 179-184.

Depression & Anxiety Neuroscience Group
Group leader: A/Prof. Ben Harrison, PhD.

  1. Davey CG, Pujol J, Breakspear M, Harrison BJ. A brain model of disturbed self appraisal in depression. The American Journal of Psychiatry. In Press.
  2. Fullana, M.A., Harrison, B.J., et al. 2016. Neural signatures of human fear conditioning: an updated and extended meta-analysis of fMRI studies. Molecular Psychiatry 21, 500-508.
  3. Schmaal, L., et al. 2016. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Molecular Psychiatry. In Press.
  4. Harrison, B.J., et al. 2013. Brain corticostriatal systems and the major clinical symptom dimensions of obsessive-compulsive disorder. Biological Psychiatry 73, 321-328.
  5. Fornito, A., Harrison, B.J., Zalesky, A., Simons, J.S., 2012. Competitive and cooperative dynamics of large-scale brain functional networks supporting recollection. Proc Natl Acad Sci U S A 109, 12788-12793.

Social and Affective NeuroDevelopment Group
Group leader: A/Prof. Sarah Whittle, PhD

  1. Richmond, Johnson, Seal, Allen and Whittle. (2016). Development of brain networks and relevance of environmental and genetic factors: A systematic review. Neuroscience & Biobehavioral Reviews 71, 215-239.
  2. Vijayakimar, Allen, Youssef, Dennison, Yucel, Simmons, Whittle. (2016).  Brain development during adolescence: a mixed-longitudinal investigation of cortical thickness, surface area, and volume. Human Brain Mapping 36(7), 2027–2038.
  3. Whittle et al. (2014). Structural brain development and depression onset during adolescence: a longitudinal, prospective study. The American Journal of Psychiatry 171(5): 564-571.
  4. Whittle et al. (2013). Childhood maltreatment and psychopathology affect brain development during adolescence. Journal of the American Academy of Child and Adolescent Psychiatry I52: 940-952.
  5. Cheetham et al. (2012). Orbitofrontal Volumes in Early Adolescence Predict Initiation of Cannabis Use: A 4-Year Longitudinal and Prospective Study. Biological Psychiatry 71(8): 684-92.

Systems Neuropsychiatry Group
Group leader: Dr Andrew Zalesky, PhD.

  1. Fornito A, Zalesky A, Bullmore E. (2016). Fundamentals of Brain Network Analysis, Academic Press (Elsevier). 450+ page authored textbook. Resides in top-10% most read neuroscience books published by Elsevier in 2016.
  2. Zalesky A et al., (2014). Time-resolved resting-state brain networks. Proc Natl Acad Sci U S A 111, 10341-10346.
  3. Zalesky A et al., (2012). Effects of long term cannabis use on axonal fibre connectivity. Brain 135, 2245-2255.
  4. Fornito A, Zalesky A, Breakspear M. (2015). The connectomics of brain disorders. Nature Reviews Neuroscience 16, 159-172.
  5. Zalesky A et al., (2015). Delayed development of brain connectivity in adolescents with schizophrenia and their unaffected siblings. JAMA Psychiatry 72; 900-908.

Gene-Environment Neuropsychiatry Group
Group leader: Dr Chad Bousman, MPH, PhD

  1. Liu, Bousman et al. (2017). Pathway-wide association study identifies five shared pathways associated with schizophrenia in three ancestral distinct populations. Translational Psychiatry 7(2), e1037.
  2. Bousman et al. (2017). Polygenic phenotypic plasticity moderates the effects of severe childhood abuse on depressive symptom severity in adulthood: A 5-year prospective cohort study. The World Journal of Biological Psychiatry, 18(1): 75-81.
  3. Bousman and Hopwood. (2016). Commercial pharmacogenetic-based decision support tools in psychiatry. The Lancet Psychiatry, 3(6): 585-90.
  4. Bousman et al. (2013). Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis. Translational Psychiatry, 3(4), e251.
  5. Singh, Bousman, et al. (2012). ABCB1 Polymorphism Predicts Escitalopram Dose Needed for Remission in Major Depression. Translational Psychiatry, 2(11), e198.

Our Research

Our Publications